A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

NCT06878625 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer

Interventions

COMBINATION_PRODUCT: Sacituzumab Govitecan combined with Toripalimab
COMBINATION_PRODUCT: Sacituzumab govitecan combined with anti-angiogenesis

Sponsor

Tianjin Medical University Cancer Institute and Hospital